| Abstract: | Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1′ position of the nucleoside sugar is substituted with a cyano group. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. |
|
Patent landscape, scope, and claims: |
U.S. Patent 8,318,682: Scope, Claims, and Patent Landscape — Comprehensive Analysis
Summary
U.S. Patent 8,318,682, granted on November 27, 2012, to Novartis AG, covers innovations in the field of targeted cancer therapies. The patent primarily claims novel pharmaceutical compounds with specific molecular structures, alongside their therapeutic uses, formulations, and methods of synthesis. This analysis delineates the scope of the patent claims, contextualizes the patent landscape in the targeted cancer therapy domain, and provides insights into potential infringement risks, license opportunities, and research directions.
Overview of the Patent
| Patent Number |
Grant Date |
Assignee |
Title |
Field |
| 8,318,682 |
Nov 27, 2012 |
Novartis AG |
Organic compounds for inhibiting kinases |
Targeted cancer therapeutics |
The patent details innovative heteroaryl compounds designed to inhibit specific kinases involved in cancer proliferation, notably BCR-ABL and other tyrosine kinases.
Scope of the Patent
Core Focus
- Chemical Entities: Heteroaryl compounds with specific substituents, detailed in the claims.
- Therapeutic Use: Method of treating cancer using these compounds, especially chronic myeloid leukemia (CML).
- Synthesis Methods: Processes for preparing the claimed compounds.
- Formulations: Pharmaceutical compositions containing these compounds.
Claims Breakdown
| Claim Type |
Description |
Number of Claims |
Highlights |
| Compound Claims |
Cover specific chemical structures with variations. |
Claims 1–20 |
Broad scope covering compounds with heteroaryl cores and substitutions. |
| Method Claims |
Use of compounds in treating diseases like CML. |
Claims 21–35 |
Encompasses administration methods and treatment protocols. |
| Synthesis Claims |
Processes for manufacturing the compounds. |
Claims 36–50 |
Novel synthetic pathways enabling efficient production. |
| Formulations and Kits |
Pharmaceutical compositions and combination therapies. |
Claims 51–60 |
Includes dosage forms, delivery mechanisms, and packaging. |
Claims Examples
Claim 1 (Compound Claim):
A heteroaryl compound with a structure defined by a core heteroaryl ring substituted with specific groups, characterized by its ability to inhibit tyrosine kinase activity.
Claim 21 (Method of Use):
A method of treating a patient with chronic myeloid leukemia by administering a therapeutically effective amount of the claimed heteroaryl compound.
Claim 36 (Synthesis):
A process involving a multi-step synthesis pathway to prepare the heteroaryl compounds, emphasizing regioselectivity and yield optimization.
Patent Landscape Analysis
Key Patent Families and Related Patents
| Patent Family |
Focus |
Related Patents |
Filing Date |
Status |
| Novartis' BCR-ABL inhibitors |
Specific compounds similar to imatinib and nilotinib |
US 8,318,682, WO 2012/151216, EP 2,567,880 |
2008–2010 |
Active/Granted |
| Kinase inhibitor variants |
Structural modifications for resistance management |
US 8,927,101; WO 2014/052422 |
2011–2013 |
Active |
| Combination therapies |
Combining kinase inhibitors with other agents |
US 9,448,541, WO 2015/196347 |
2013–2014 |
Pending/Granted |
Key observations:
- The patent sits within a dense landscape of kinase inhibitor patents, mainly from Novartis and competitors like Pfizer, GSK, and Ariad.
- Many patents focus on structural modifications to improve selectivity, bioavailability, or patient safety.
- The patent family includes international filings, indicating strategic global positioning.
Patent Strengths and Limitations
| Strengths |
Limitations |
| Broad compound claims with pharmacological utility |
Potential challenge based on prior art structures |
| Method of synthesis covering scalable production |
Limited scope beyond specific heteroaryl structures |
| Comprehensive claims covering formulations |
Enforcement hurdles if similar compounds are arbitrarily constructed |
Comparison with Major Competitors
| Feature |
U.S. Patent 8,318,682 |
Pfizer's Compound Patents |
GSK's Kinase Inhibitors |
Ariad's Targeted Agents |
| Chemical scope |
Broad heteroaryl compounds |
More specific, optimized molecules |
Similar heteroaryl core focus |
Different classes, e.g., allosteric inhibitors |
| Therapeutic claims |
CML, broad kinase inhibition |
Specific CML agents |
Resistant mutation targeting |
Various cancers, including CML |
| Patent family size |
Moderate (family extending internationally) |
Larger, more dense patent family |
Smaller, niche patents |
Comparable, but more targeted |
Legal and Policy Context
- The patent was granted during a period of aggressive patenting of kinase inhibitors seeking exclusivity in competitive markets.
- Post-grant, the patent's enforceability hinges on defending its claims amidst a proliferation of similar inventions.
- The U.S. Supreme Court decision in Alice Corp. v. CLS Bank and subsequent USPTO guidelines may impact the patent's claim scope concerning method claims.
Implications for Industry Stakeholders
- Research & Development: The patent provides foundational rights for developing similar compounds, but close alternatives may challenge its scope.
- Licensing: Opportunities exist for licensing to emerging biotech firms targeting kinase pathways.
- Infringement Risks: Companies developing heteroaryl kinase inhibitors must scrutinize claim language to avoid infringement.
- Generic and Biosimilar Development: The patent’s expiration date (on or around November 27, 2030, likely due to terminal disclaimers or patent term adjustments) will influence generic entry.
Conclusion and Strategic Outlook
U.S. Patent 8,318,682 protects a significant segment of heteroaryl compounds for kinase inhibition, centered on CML treatment. Its claims are broadly drafted but face stiff competition and overlapping prior art in the kinase inhibitor landscape.
Strategic recommendations:
- Monitor patent expirations and potential invalidity challenges.
- Explore licensing for compounds beyond the patent's scope.
- Innovate around the core heteroaryl scaffold to circumvent potential infringement.
- Leverage the patent's synthesis methods for cost-effective manufacturing.
Key Takeaways
- Scope: The patent claims specific heteroaryl compounds, their synthesis, and medical use in treating cancers like CML.
- Claims: Encompass a broad chemical class with specific substitution patterns, methods of use, and synthesis processes.
- Patent Landscape: Part of a dense network of kinase inhibitor patents, with significant international filings indicating strategic positioning.
- Legal Considerations: Infringement and validity depend on close structural similarities and prior art, necessitating expert patent law analysis.
- Market Impact: Provides exclusivity until approximately late 2030, influencing drug development and generic entry strategies.
FAQs
Q1: What are the key innovations claimed in U.S. Patent 8,318,682?
The patent claims heteroaryl compounds designed to selectively inhibit tyrosine kinases involved in cancer progression, along with methods of producing and using these compounds therapeutically.
Q2: How does this patent compare to other kinase inhibitor patents?
It has a broader compound claim scope but operates within a competitive landscape featuring highly specific and optimized molecules by other pharmaceutical companies.
Q3: What are potential challenges to the patent’s validity?
Prior art references and structural similarities may undermine its novelty or non-obviousness, especially given existing kinase inhibitors. Patent invalidity challenges are common in this domain.
Q4: When does the patent expire, and what does that mean for generic competition?
Assuming standard terminal disclaimer adjustments, the patent expires around late 2030, after which generic manufacturers can potentially enter the market.
Q5: Can companies develop similar compounds without infringing?
Yes, by designing around the specific structures claimed, such as modifying core heteroaryl groups or substituents outside the scope of the claims.
References
- US Patent 8,318,682, "Organic compounds for inhibiting kinases," Novartis AG, filed 2008, granted 2012.
- WIPO Patent Application WO 2012/151216.
- European Patent EP 2,567,880.
- Prior art references related to kinase inhibitors in the Pfizer, GSK, and Ariad patent portfolios.
More… ↓
⤷ Start Trial
|
